Helixmith Co Ltd (Helixmith), discovers and develops DNA, protein-based therapeutics, herbal medicines and nutraceuticals for treating various ischemic diseases or neurodegenerative disorders. The company developed Engensis (VM202), a plasmid DNA therapy used to express two isoforms of hepatocyte growth factor and treat various neurodegenerative diseases such as diabetic peripheral neuropathy, diabetic foot ulcer and coronary artery disease. It develops a VM206 program for treating breast cancer and a VM501 program against thrombocytopenia, a deficiency of blood platelets caused due to chemotherapy. Helixmith also investigating various programs to treat chronic wounds, peripheral arterial diseases and claudication. The company uses plasmid DNA (pCK) and AAV vector technology to treat neuromuscular and muscle diseases. It has a manufacturing facility in San Diego, California, the US. Helixmith is headquartered in Seoul, South Korea.
Headquarters
South Korea
Address
21, Magokjungang 8-Ro 7-Gil, Gangseo-Gu, Seoul, 07794
Website
helixmith.com
Telephone
82 2 21027200
No of Employees
72
Industry
Pharmaceuticals and Healthcare
Ticker Symbol & Exchange
084990 (KDQ)
Revenue (2022)
$2.2M
50.1%
(2022 vs 2021)
EPS
XYZ
Net Income (2022)
XYZ
-47.2%
(2022 vs 2021)
Market Cap*
$148.1M
Net Profit Margin (2022)
XYZ
1.9%
(2022 vs 2021)
* As of and is in US$
Helixmith Co Ltd premium industry data and analytics
Products and Services
| Products |
|---|
| Gene Therapy |
| Engensis (VM202): |
| Amyotrophic Lateral Sclerosis |
| XYZ |
| XYZ |
| XYZ |
Competitor Comparison
| Key Parameters | Helixmith Co Ltd | Daihan Pharm Co Ltd | Ctcbio Inc | iNtRON Biotechnology Inc | Genexine Inc |
|---|---|---|---|---|---|
| Headquarters | South Korea | South Korea | South Korea | South Korea | South Korea |
| City | Seoul | Seoul | Hwaseong | Seongnam | Seoul |
| No. of Employees | 72 | 721 | 258 | 77 | 161 |
| Entity Type | Public | Public | Public | Public | Public |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Sunyoung Kim | Chief Executive Officer; Director | Executive Board | - | 68 |
| Yoo Seung Shin | Chief Executive Officer; Director | Executive Board | - | 57 |
| Dongkyu Choi | Director | Non Executive Board | - | 64 |
| Hoonsik Kim | Director | Non Executive Board | - | 61 |
| Park Jae-seok | Director | Non Executive Board | - | 58 |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward